Gut bacteria study in lymphoma treated with glofitamab
Part of Cancer, Digestive system clinical trials.
This study looks at how the natural bacteria in your gut (your microbiome) affect your response to the drug glofitamab for DLBCL. Participating could help doctors understand why some people respond better and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), a type of blood cancer.
- Your doctor must plan to treat you with the drug glofitamab (an immunotherapy that helps your immune system attack cancer cells).
- You must be willing to give written consent to participate.
- You should not have any serious uncontrolled medical conditions that could affect the study.
- You must not have another type of cancer at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a medicine called glofitamab works and how safe it is for people with a type of blood cancer (diffuse large B-cell lymphoma) that did not respond to first treatment or came back within a year. If you qualify, you may receive glofitamab as part of your care, and the study will track your progress.
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This study looks at how well glofitamab works in real-world patients with a type of lymphoma that has come back or not responded to treatment. It includes adults who have already received obinutuzumab and at least one dose of glofitamab in a special access program.
This trial tests a drug called glofitamab for people with aggressive B-cell lymphomas (like DLBCL or mantle cell lymphoma) that have come back or not responded to standard treatments. The study uses a biopsy during treatment to see how the drug is working, aiming to make treatment more personalized.
This study looks at how well a new drug called glofitamab works in real life for people with a type of lymphoma that has come back or not improved after treatment. It aims to see if the drug is safe and effective outside of a clinical trial setting.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.